SDZ Share Price Performance
CHF 67.60
27.85 (70.06%)
15.7% overvalued intrinsic discount
CHF 58.42
Fair Value
Price CHF 67.60
AnalystConsensusTarget CHF 58.42
AnalystLowTarget CHF 42.87
AnalystHighTarget CHF 60.37
Fair ValueCHF 58.42
Share Pricen/a
Sandoz Group AG Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 54 Fair Values set on narratives written by author
SDZ Community Narratives
AN
Fair Value CHF 58.42 15.7% overvalued intrinsic discount
Future Opportunities Will Be Unlocked Through Expanding Pipeline And Global Market Reach
1users have liked this narrative
0users have commented on this narrative
32users have followed this narrative
AN
Fair Value CHF 42.87 57.7% overvalued intrinsic discount
Rising Regulatory Hurdles And US Tariffs Will Undermine Biosimilar Margins
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value CHF 60.37 12.0% overvalued intrinsic discount
Rising Healthcare Demand And Aging Populations Will Accelerate Biosimilar Adoption
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Future Opportunities Will Be Unlocked Through Expanding Pipeline And Global Market Reach
Key Takeaways Accelerated biosimilar launches, improved manufacturing, and strong market share are driving margin expansion and long-term profitability. Strategic focus on international growth and a robust product pipeline positions the company for sustainable earnings momentum.Read more
113
users have viewed this narrative1users have liked this narrative
0users have commented on this narrative
32users have followed this narrative
AN
CHF 58.42
15.7% overvalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
6.78% p.a.
Profit Margin
13.3%
Future PE
21.4x
Price in 2029
CHF 65.56
Rising Regulatory Hurdles And US Tariffs Will Undermine Biosimilar Margins
Key Takeaways Sustained pricing and regulatory pressures, along with rising legal risks, are likely to constrain revenue growth and earnings quality for Sandoz. Increased investment and competition may erode margins and threaten the long-term viability of its traditional generics and biosimilars business model.Read more
31
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
CHF 42.87
57.7% overvalued intrinsic discount
AnalystLowTarget's Fair Value
Revenue
7.12% p.a.
Profit Margin
13.81%
Future PE
15.01x
Price in 2029
CHF 48.36
Rising Healthcare Demand And Aging Populations Will Accelerate Biosimilar Adoption
Key Takeaways Rapid biosimilars adoption and manufacturing innovation are driving above-expected revenue growth, margin expansion, and sustainable profitability. Strong presence in emerging markets and expanding product pipeline enable diversified, resilient growth and long-term earnings acceleration.Read more
10
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
CHF 60.37
12.0% overvalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
8.87% p.a.
Profit Margin
15.34%
Future PE
17.53x
Price in 2028
CHF 67.36
Trending Discussion
Recently Updated Narratives
AN
SDZ: Richer Future P/E Assumptions Will Test Biosimilar Execution Confidence
Fair Value: CHF 58.42 15.7% overvalued intrinsic discount
32 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
SDZ: Elevated Expectations Will Confront Ongoing Execution And Manufacturing Setbacks
Fair Value: CHF 42.87 57.7% overvalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Rising Healthcare Demand And Aging Populations Will Accelerate Biosimilar Adoption
Fair Value: CHF 60.37 12.0% overvalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Sandoz Group AG Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
Aug 05, 2026
- 2.11
- 47.50%
- 8.19%
- 56.6%
About SDZ
- Founded
- 1886
- Employees
- 22356
- CEO
- WebsiteView website
Sandoz Group AG develops, manufactures, and markets generic and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, supportive care, rare diseases, diabetes, immunology, endocrinology, neurology, osteoporosis, nephrology, hematology, and ophthalmology. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. Sandoz Group AG was founded in 1886 and is headquartered in Basel, Switzerland.
